Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
Summary
- Conditions
- Heart Failure
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Retrospective
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
Index date will be date of 1st prescription of sacubitril/valsartan. Dose titration of sacubitril/valsartan will be assessed for a period of 6 months post index date.
Index date will be date of 1st prescription of sacubitril/valsartan. Dose titration of sacubitril/valsartan will be assessed for a period of 6 months post index date.
Tracking Information
- NCT #
- NCT04735354
- Collaborators
- Not Provided
- Investigators
- Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Get Well Soon